|

A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy

RECRUITINGPhase 2Sponsored by Vima Therapeutics
Actively Recruiting
PhasePhase 2
SponsorVima Therapeutics
Started2026-09
Est. completion2027-06
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
Locations29 sites

Summary

Vista PD is a randomized, placebo-controlled, multicenter study to evaluate the efficacy, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy. The main objectives of this clinical trial are to determine the following: * Does VIM0423 therapy improve tremor symptoms in adults with Parkinson's disease? * Is VIM0423 well tolerated in individuals with Parkinsons's disease? and * Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria

* Participant must be male or nonpregnant female between 18 and 65 years of age (inclusive) at Visit 1 (Screening).
* Diagnosis of clinically probable or clinically established idiopathic Parkinson's disease (PD) at Visit 1 (Screening) established by the MDS 2015 criteria which must include tremor as one of the cardinal characteristics.
* Cohort 1: Currently using levodopa (any oral form only) or oral dopamine agonist at a stable dose and regimen of at least 10 weeks prior to Visit 1 (Screening); with no anticipated changes to said therapies for the duration of the study; and on a minimum of 300 mg LEDD. Cohort 2: Individuals who are dopaminergic naïve, as defined by: no prior or ongoing usage of levodopa (in any form) or dopamine agonist (in any form), and no anticipated plans to initiate said therapies for the duration of the study.
* The participants must meet protocol-specified requirements for baseline tremor scores.

Exclusion Criteria

* Currently (within 7 days of Screening) taking any anticholinergic medication.
* Prior deep brain stimulation (DBS) or any other form of invasive neurosurgical intervention (including, but not limited to, magnetic resonance-guided focused ultrasound thalamotomy, ablative thalamotomy, gamma knife thalamotomy)

Other protocol-specified inclusion and exclusion criteria may apply.

Conditions2

PARKINSON DISEASE (Disorder)Parkinson's Disease

Interventions2

Locations29 sites

Vima Site #039
Scottsdale, Arizona, 85251
Study Director617-430-7027clinicaltrials@vimatx.com
Vima Site #064
Scottsdale, Arizona, 85258
Study Director617-430-7027clinicaltrials@vimatx.com
Vima Site #048
Murrieta, California, 92562
Study Director617-430-7027clinicaltrials@vimatx.com
Vima Site #050
Stamford, Connecticut, 06905
Study Director617-430-7027clinicaltrials@vimatx.com
Vima Site #065
Altamonte Springs, Florida, 32714
Study Director617-430-7027clinicaltrials@vimatx.com

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.